Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | ALKBH2 | Q6NS38 | 2/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | ALKBH1 | Q13686 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31681673 | 0.83 | L3MBTL1 (0.67) | L3MBTL1ALKBH2HPGDSHSD17B10EGLN1 | |
| SCHEMBL29954606 | 0.82 | L3MBTL1 (0.65) | L3MBTL1ALKBH2HPGDSHSD17B10EGLN1 | |
| SCHEMBL28316059 | 0.80 | L3MBTL1 (0.62) | L3MBTL1ALKBH2HPGDSHSD17B10EGLN1 | |
| SCHEMBL28578166 | 0.80 | L3MBTL1 (0.62) | L3MBTL1ALKBH2HPGDSHSD17B10EGLN1 | |
| SCHEMBL4022892 | 0.80 | L3MBTL1 (0.62) | L3MBTL1ALKBH2HPGDSHSD17B10EGLN1 | |
| SCHEMBL553834 | 0.80 | L3MBTL1 (0.73) | L3MBTL1ALKBH2HPGDSHSD17B10EGLN1 | |
| SCHEMBL27681525 | 0.79 | L3MBTL1 (0.57) | L3MBTL1ALKBH2HPGDSHSD17B10EGLN1 | |
| Hydrochloric Acid SCHEMBL4758885 | 0.78 | L3MBTL1 (0.71) | L3MBTL1ALKBH2HPGDSHSD17B10EGLN1 | |
| SCHEMBL18038382 | 0.78 | L3MBTL1 (0.71) | L3MBTL1ALKBH2HPGDSHSD17B10EGLN1 | |
| SCHEMBL4899184 | 0.78 | L3MBTL1 (0.44) | L3MBTL1ACHEPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. | 2008-10-02 | — | — | US | disclosed |
| CN-1894206-A | N-substituted N-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC (JP) | 2007-01-10 | — | — | CN | disclosed |
| EP-1694638-A1 | N-SUBSTITUTED-N-SULFONYLAMINOCYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20050222146-A1 | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2005-10-06 | — | — | US | disclosed |
| WO-2005058808-A1 | N-SUBSTITUTED-N-SULFONYLAMINOCYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | MMP13, MMP11, MMP3 | L3MBTL1 2711/4885ALKBH2 2140/4885HPGDS 1402/4885 |
| US-20050222146-A1 | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | MMP13, MMP11, MMP1 | L3MBTL1 2844/4885ALKBH2 2204/4885HPGDS 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.